Ｄｏｗｎ症候群の白血病発症の分子機構

DOI 被引用文献5件 参考文献58件

書誌事項

タイトル別名
  • The Molecular Mechanism of Leukemogenesis in Down's Syndrome

この論文をさがす

抄録

Children with Down's syndrome have an approximately 20-fold higher incidence of leukemia than unaffected children. The majority of leukemia cases associated with Down's syndrome are acute megakaryocytic leukemia (AMKL). Recently, we and others have demonstrated that mutagenesis of the GATA-1 gene, encoding the erythroid/megakaryocytic transcription factor GATA-1, is a very early event in the development of Down's syndrome-related AMKL (DS-AMKL) in the process of multi-step leukemogenesis. Acquired mutations of the GATA-1 gene have been detected in almost all cases in DS-AMKL and transient myeloproliferative disorder (TMD), “a preleukemia” that may be present in as many as 10% of newborn infants with Down's syndrome. In each, the mutation resulted in the introduction of a premature stop codon in the gene sequence that encodes the N-terminal activation domain and a complete lack of expression of the 50-kD full length GATA-1 protein. Instead, an alternative 40-1W translation product of GATA-1 was expressed from a downstream initiation site. Human tumors have been shown to progress by the accumulation of genetic abnormalities. DS-AMKL is an excellent model of cancer pathogenesis. To understand the mechanisms of a lineage-specific malignant conversion further, it is very important to define the mechanism that results in the high frequency of GATA-1 mutations in Down's syndrome, and to identify the gene or genes on chromosome 21 which cooperate with mutated GATA-1, as well as additional genetic changes in TMD blast cells during the development of DS-AMKL.

収録刊行物

被引用文献 (5)*注記

もっと見る

参考文献 (58)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ